Frontline Anlotinib Plus CapeOX Elicits Similar Efficacy to SOC Therapy in RAS/BRAF Wild-Type mCRC
Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.
Related Articles
Dr Mehnert on the Efficacy of Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab in Unresectable Melanoma
Janice M. Mehnert, MD, discusses the efficacy and safety profile of sarilumab plus ipilimumab, nivolumab, and relatimab in unresectable melanoma.
Molecular Profiling in Pancreatic Cancer: RAS Testing and Codon-Specific Interpretation
Panelists highlighted how recent breakthroughs in KRAS-specific inhibitors—such as those targeting G12C, G12D, and G12V mutations—are transforming the management of pancreatic cancer, underscoring the importance…
Oncologists Highlight Key Takeaways and Abstracts From the 2025 ESMO GI Cancers Congress
Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.
LUMINOSITY Data Continue to Highlight Utility of Telisotuzumab Vedotin in c-MET–Overexpressing NSCLC
Jonathan Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET–overexpressing, nonsquamous, EGFR wild-type advanced NSCLC.
FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC
The FDA declined to expand the label for talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.
Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia
Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.
Retifanlimab Presents a New Treatment Option for Locally Recurrent or Metastatic SCAC
Cathy Eng, MD, FACP, FASCO, highlights the significance of the FDA approval of retifanlimab for managing locally recurrent or metastatic SCAC.
Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL
Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.
VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS
Venetoclax plus azacitidine did not yield an OS benefit vs placebo plus azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes.
Using Self-Directed Learning to Combat Information Overload in Oncology Fellowship
Jill Gilbert, MD, discusses how principles of adult learning theory can be applied to hematology/oncology fellowship.